2. Cell Cycle/DNA Damage Epigenetics Apoptosis Immunology/Inflammation NF-κB Metabolic Enzyme/Protease
  3. Sirtuin Apoptosis MDM-2/p53 Reactive Oxygen Species (ROS) Bcl-2 Family Caspase
  4. Rehmannioside D

Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis.

For research use only. We do not sell to patients.

Rehmannioside D

Rehmannioside D Chemical Structure

CAS No. : 81720-08-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in Water In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Rehmannioside D:

Rehmannioside D Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Rehmannioside D

View All Sirtuin Isoform Specific Products:

View All Isoforms
Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7 SIRT4

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis[1][2].

In Vitro

Rehmannioside D (5-10 μM; 24 h) alleviates H2O2-induced apoptosis of AML12 cells by upregulating Sirt7 expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rehmannioside D Related Antibodies

Apoptosis Analysis[1]

Cell Line: H2O2-injured AML12 hepatocytes
Concentration: 5 μM; 10 μM
Incubation Time: 24 h (co-incubation with H2O2)
Result: Significantly reduced the proportion of apoptotic AML12 cells induced by H2O2, with both 5 μM and 10 μM doses yielding statistically significant effects.
Increased nuclear Sirt7 protein expression, decreased nuclear acetyl-p53 levels, reduced the Bax/Bcl2 ratio, and lowered Cleaved-caspase 3 levels compared to H2O2-only treated cells.
In Vivo

Rehmannioside D (10-40 mg/kg; i.g.; daily; 3 weeks) attenuates CCl4-induced liver fibrosis in male C57BL/6J mice[1].
Rehmannioside D (10-40 mg/kg; p.o.; daily; 2 weeks) attenuates DMN-induced liver fibrosis in male Wistar rats by upregulating Sirt7 expression, inhibiting acetyl-p53-mediated hepatocyte apoptosis, reducing hepatic injury, inflammation, and collagen deposition[1].
Rehmannioside D (19-76 mg/kg; i.g.; daily; 2 weeks) has an ameliorative effect in a rat model of impaired ovarian reserve[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 22-24 g, CCl4-induced liver fibrosis model)[1]
Dosage: 10 mg/kg; 40 mg/kg
Administration: i.g.; daily; 3 weeks
Result: Significantly reduced serum ALT and AST activities compared to CCl4-induced controls.
Ameliorated liver histopathological damage, including reduced lobule structural distortion, hepatocellular swelling/necrosis, and inflammatory cell infiltration.
Decreased F4/80-positive macrophage area and downregulated hepatic mRNA expression of inflammatory genes (Adgre1, Tnfα, Il1β, Ccl2) compared to CCl4-induced controls.
Reduced collagen deposition.
Reduced the number of TUNEL+/HNF4α+ hepatocytes compared to CCl4-induced controls.
Restored hepatic Sirt7 expression, reduced nuclear acetyl-p53 levels, lowered the Bax/Bcl2 ratio, and decreased Cleaved-caspase 3 levels compared to CCl4-induced controls.
Animal Model: SD rats (female, 8 weeks old, Cyclophosphamide (HY-17420) induced DOR)[3]
Dosage: 19 mg/kg, 38 mg/kg, 76 mg/kg
Administration: i.g.; daily; 2 weeks
Result: Notably recovered disordered estrous cycles and increased ovarian index of DOR rats.
Elevated the quantity of primordial and mature follicles while reducing atretic follicle count via ovarian histomorphology observation.
Downregulated abnormally high FSH and LH concentrations and upregulated declined E2 level.
Decreased granulosa cell apoptotic rate and upregulated FOXO1 expression.
Molecular Weight

686.61

Formula

C27H42O20
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@@]([C@](C(CO)=C1)([H])[C@@H]2O[C@]([C@@H]([C@@H](O)[C@@H]3O)O)([H])O[C@@H]3CO)(C=CO2)O[C@@](O[C@H](CO)[C@@H](O)[C@@H]4O)([H])[C@@H]4O[C@]([C@@H]([C@@H](O)[C@@H]5O)O)([H])O[C@@H]5CO
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

H2O : 100 mg/mL (145.64 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.4564 mL 7.2822 mL 14.5643 mL
5 mM 0.2913 mL 1.4564 mL 2.9129 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.89%

SDS (392 KB)

COA (261 KB) HNMR (418 KB) RP-HPLC (243 KB) LCMS (87 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 1.4564 mL 7.2822 mL 14.5643 mL 36.4108 mL
5 mM 0.2913 mL 1.4564 mL 2.9129 mL 7.2822 mL
10 mM 0.1456 mL 0.7282 mL 1.4564 mL 3.6411 mL
15 mM 0.0971 mL 0.4855 mL 0.9710 mL 2.4274 mL
20 mM 0.0728 mL 0.3641 mL 0.7282 mL 1.8205 mL
25 mM 0.0583 mL 0.2913 mL 0.5826 mL 1.4564 mL
30 mM 0.0485 mL 0.2427 mL 0.4855 mL 1.2137 mL
40 mM 0.0364 mL 0.1821 mL 0.3641 mL 0.9103 mL
50 mM 0.0291 mL 0.1456 mL 0.2913 mL 0.7282 mL
60 mM 0.0243 mL 0.1214 mL 0.2427 mL 0.6068 mL
80 mM 0.0182 mL 0.0910 mL 0.1821 mL 0.4551 mL
100 mM 0.0146 mL 0.0728 mL 0.1456 mL 0.3641 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rehmannioside D Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rehmannioside D81720-08-3SirtuinApoptosisMDM-2/p53Reactive Oxygen Species (ROS)Bcl-2 FamilyCaspasep53 signaling pathwayhepatic injurySirtuin 7Rehmannia glutinosaSirt7liver fibrosisC57BL/6J miceWistar ratsacetyl-p53AML12 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Rehmannioside D
Cat. No.:
HY-N0912
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB) Italian - IT (392 KB) Korean - KR (392 KB) Portuguese - PT (392 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.